HC Wainwright reaffirmed their buy rating on shares of Palisade Bio (NASDAQ:PALI – Free Report) in a research note released on Wednesday,Benzinga reports. They currently have a $7.00 price target on the stock.
A number of other research analysts also recently commented on the stock. LADENBURG THALM/SH SH raised shares of Palisade Bio to a “strong-buy” rating in a report on Thursday, June 25th. Oppenheimer initiated coverage on Palisade Bio in a research note on Thursday, July 23rd. They set an “outperform” rating and a $8.00 price objective on the stock. Weiss Ratings downgraded Palisade Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, July 14th. Finally, Wall Street Zen raised Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, July 25th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Palisade Bio has an average rating of “Buy” and an average price target of $9.83.
Get Our Latest Stock Report on Palisade Bio
Palisade Bio Stock Down 7.6%
Palisade Bio (NASDAQ:PALI – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). The business had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.50 million. On average, equities research analysts anticipate that Palisade Bio will post -0.23 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other news, Director Robert Baltera purchased 25,000 shares of the company’s stock in a transaction dated Thursday, July 9th. The shares were acquired at an average price of $1.96 per share, with a total value of $49,000.00. Following the transaction, the director owned 461,904 shares of the company’s stock, valued at $905,331.84. This represents a 5.72% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mitchell Jones sold 51,880 shares of Palisade Bio stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $2.05, for a total value of $106,354.00. Following the completion of the sale, the insider owned 94,009 shares of the company’s stock, valued at $192,718.45. The trade was a 35.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders bought 125,000 shares of company stock worth $250,100. 0.07% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Palisade Bio
Several large investors have recently modified their holdings of the business. WINTON GROUP Ltd raised its stake in Palisade Bio by 180.2% in the second quarter. WINTON GROUP Ltd now owns 32,227 shares of the company’s stock worth $67,000 after buying an additional 20,727 shares in the last quarter. PCG Wealth Advisors LLC purchased a new stake in Palisade Bio during the second quarter worth $86,000. Susquehanna International Group LLP bought a new stake in Palisade Bio during the 2nd quarter valued at $65,000. Two Sigma Securities LLC bought a new stake in Palisade Bio during the 2nd quarter valued at $57,000. Finally, Wellington Management Group LLP increased its holdings in shares of Palisade Bio by 27.5% in the 2nd quarter. Wellington Management Group LLP now owns 3,703,936 shares of the company’s stock valued at $7,741,000 after acquiring an additional 799,025 shares during the period. Institutional investors own 11.79% of the company’s stock.
Trending Headlines about Palisade Bio
Here are the key news stories impacting Palisade Bio this week:
- Positive Sentiment: Health Canada cleared the company’s clinical trial application for the global Phase 2 ASCENTRA-UC study of PALI-2108 in ulcerative colitis. The clearance allows the program to advance toward broader clinical testing and is a meaningful regulatory milestone. Palisade Bio Receives Health Canada CTA Clearance
- Positive Sentiment: Palisade Bio also received FDA clearance for the PALI-2108 investigational new drug application in Crohn’s disease, supporting development of the company’s PDE4 inhibitor platform in another inflammatory bowel disease indication. Palisade Bio Gets FDA Clearance for PALI-2108
- Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating, while other analyst coverage characterized PALI favorably. These endorsements may support investor sentiment, although they do not guarantee clinical or commercial success. HC Wainwright Reaffirms Buy Rating
- Neutral Sentiment: A reported September short-interest figure of zero shares implies no measurable short positioning, but the item also describes a “large increase,” indicating the data may be inconsistent and should be interpreted cautiously.
- Negative Sentiment: One report said Palisade backed away from an FSCD-related opportunity. Without additional details, the development could raise questions about strategic priorities, though its direct financial impact is unclear. Palisade Backs Away from FSCD
Palisade Bio Company Profile
Palisade Bio, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for gastrointestinal diseases and conditions associated with intestinal inflammation, impaired gut-barrier function and complications following surgery.
The company’s lead product candidate is LB1148, an orally administered, non-absorbed pan-serine protease inhibitor. Palisade Bio is evaluating LB1148 for its potential to limit the harmful effects of digestive enzymes, reduce inflammation and support intestinal healing during the postoperative period.
Featured Stories
- Five stocks we like better than Palisade Bio
- Costco Ends Its Fiscal Year on a High Note, Eyes Big Expansion
- Cracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic Problem
- Oracle’s Force Majeure Notice Exposes a Bigger Problem for the AI Build-Out
- Oil May Be Stronger Than It Looks—And Diamondback Is on Sale
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
